KRAS mutations, which are found in approximately 25%–30% of NSCLC cases, compound these challenges, as they are commonly associated with chemotherapy resistance and the absence of effective targeted therapies, leading to poorer patient outcomes [33]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.